Drugs / Esmolol
Esmolol
also known as
Esmolol Hydrochloride · Brevibloc · ASL-8052 · ASL-8052-001 · breviblock · Clol · Esmolol Hcl
Other / unclassified targets ADRB1, ADRB2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | BREVIBLOC | — | 1992-12-18 | fda.gov ↗ |
| Approved | US (FDA) | BREVIBLOC | — | 1986-12-31 | fda.gov ↗ |
Trials 60
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07603596 | May 2026 → Apr 2028 expected | delirium, digestive system neoplasm | Qianfoshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07313605 | Jan 2026 → Jan 2028 expected | infectious disease with sepsis | John Basmaji | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06457100 | Nov 2023 → Jun 2024 | chronic rhinosinusitis | The Second People's Hospital of Huai'an | Unknown | No outcome recorded |
| Phase 1/2 | NCT06065956 | Aug 2022 → Jun 2023 | — | Pakistan Navy Station Shifa Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01113515 | Feb 2014 → Jun 2015 | ulcer of lower limbs | Novalead Pharma Private Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT01343329 | Jul 2011 → Feb 2014 | dysautonomia, traumatic brain injury | Johns Hopkins University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 211 trials · 1 met primary | ||||||
| Phase 2 | NCT06522594 | Jun 2024 → Dec 2025 overdue | cardiogenic shock, heart failure | Erasmus Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06390748 | Jan 2021 → Dec 2023 | T-cell immunodeficiency, cytokine release syndrome, disorder of catecholamine synthesis, infectious disease with sepsis +1 | Lin Chen | Completed | No outcome recorded |
| Phase 2 | NCT03208257 | Aug 2017 → Dec 2020 | infectious disease with sepsis | Samuel Brown | Unknown | No outcome recorded |
| Phase 2 | NCT03661346 | Mar 2017 → Mar 2018 | chronic rhinosinusitis | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 2 | NCT02841241 | Apr 2016 → Mar 2017 | infectious disease with sepsis | Intermountain Health Care, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02120404 | Apr 2015 → Oct 2023 | infectious disease with sepsis | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2 | NCT02068287 | Dec 2013 → Dec 2016 | infectious disease with sepsis | Central Hospital, Nancy, France | Unknown | No outcome recorded |
| Phase 2 | NCT02997800 | Nov 2012 → Jan 2019 | hypertensive disorder | Dr. Robert Tanzola | Completed | No outcome recorded |
| Phase 2 | NCT01231698 | Dec 2010 → Jul 2012 | infectious disease with sepsis | Andrea Morelli | Completed | Met primary |
| Phase 2 | NCT00713401 | Feb → Apr 2008 | atrial fibrillation | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00302692 | Dec 2005 → Sep 2008 | cardiovascular disorder | University of Texas Southwestern Medical Center | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02842983 | Dec 2014 → Dec 2016 | — | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT06863558 | May 2025 → Mar 2026 overdue | intracerebral hemorrhage | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06863571 | Apr 2025 → Mar 2026 overdue | ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 3 | NCT05769868 | Apr 2023 → Mar 2027 expected | cirrhosis of liver, neoplastic disease or syndrome, type 2 diabetes mellitus | Biomedical Research Networking Center (CIBER) | Recruiting | No outcome recorded |
| Phase 3 | NCT06013319 | Feb 2023 → Apr 2026 overdue | adult acute respiratory distress syndrome | Zhiming Jiang | Recruiting | No outcome recorded |
| Phase 3 | NCT02609152 | Jul 2016 → Jul 2017 | — | Nîmes University Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT01208402 | Sep 2010 → Jul 2013 | — | Duke University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00922467 | Jun → Dec 2009 | — | Hopital Foch | Terminated | No outcome recorded |
| Phase 3 | NCT00348101 | Jun 2006 → May 2007 | coronary artery disorder | Klinikum Ludwigshafen | Completed | No outcome recorded |
| Phase 419 trials · 1 missed | ||||||
| Phase 4 | NCT07019818 | Oct 2025 → Jan 2028 expected | — | University Hospital, Limoges | Recruiting | No outcome recorded |
| Phase 4 | NCT06958393 | May 2025 → Jan 2026 overdue | subacute delirium | Qianfoshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06291363 | Apr 2024 → Mar 2025 overdue | substance-related disorder | Ciusss de L'Est de l'Île de Montréal | Recruiting | No outcome recorded |
| Phase 4 | NCT05635877 | Feb 2023 → Nov 2026 expected | — | Yongtao Sun | Recruiting | No outcome recorded |
| Phase 4 | NCT05694585 | Feb → Dec 2023 | acute stress disorder, disorder of catecholamine synthesis, obstructive lung disease | Xiumei Song | Unknown | No outcome recorded |
| Phase 4 | NCT04234477 | Dec 2021 → Jun 2022 | atrial fibrillation | Boston University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05073094 | Oct 2021 → Jun 2023 | hypertrophic cardiomyopathy | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 4 | NCT04752111 | Jan → Jun 2021 | — | Benha University | Completed | No outcome recorded |
| Phase 4 | NCT03743103 | Apr 2019 → Oct 2021 | intracerebral hemorrhage | Cristália Produtos Químicos Farmacêuticos Ltda. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03549923 | Dec 2018 → Oct 2022 | cardiogenic shock | Beijing Anzhen Hospital | Completed | Missed primary |
| Phase 4 | NCT03533179 | Jun 2018 → Oct 2019 | — | University Hospital Bispebjerg and Frederiksberg | Completed | No outcome recorded |
| Phase 4 | NCT02844894 | Jun → Aug 2016 | — | Ufuk University | Unknown | No outcome recorded |
| Phase 4 | NCT01824758 | Mar → Apr 2013 | — | Ankara Diskapi Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01752959 | Jul → Dec 2012 | nose, anomalous shape of | Diskapi Teaching and Research Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01404767 | Apr 2011 | heart disorder, hypertensive disorder | University Health Network, Toronto | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01171911 | Oct → Dec 2010 | acute coronary syndrome, coronary stenosis | Nanjing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT01114997 | Apr 2010 → Jun 2015 | constipation disorder | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT01114971 | Sep 2009 → Jul 2014 | — | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00959569 | Aug 2009 → May 2018 | cardiac valvular defect | Vita-Salute San Raffaele University | Completed | No outcome recorded |
| Phase not applicable15 trials · 1 met primary | ||||||
| — | NCT07657754 | Aug 2026 → Dec 2027 expected | infectious disease with sepsis | First Affiliated Hospital of Wannan Medical College | Not yet recruiting | No outcome recorded |
| — | NCT06620991 | Oct 2024 → Apr 2025 overdue | — | Ain Shams University | Not yet recruiting | No outcome recorded |
| — | NCT05389176 | Jul 2022 → Mar 2024 | cardiac rhythm disease, infectious disease with sepsis | Chinese Medical Association | Unknown | No outcome recorded |
| — | NCT05950971 | Jul 2021 → Jan 2022 | paroxysmal atrial fibrillation | Seoul National University Hospital | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT06169475 | Nov 2020 → Nov 2021 | cerebrovascular disorder, infectious disease with sepsis | Xinchen Wang | Completed | No outcome recorded |
| — | NCT04537767 | Oct 2020 → Mar 2023 | infectious disease with sepsis | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| — | NCT04306913 | Apr → Sep 2020 | — | Kasr El Aini Hospital | Unknown | No outcome recorded |
| — | NCT01885364 | Jun → Nov 2015 | — | Kyungpook National University Hospital | Completed | No outcome recorded |
| — | NCT01232400 | Jul 2014 → Jul 2015 | subarachnoid hemorrhage | University of Michigan | Withdrawn | No outcome recorded Stop: Business |
| — | NCT02116868 | Mar 2014 → Mar 2018 | — | Central Hospital, Nancy, France | Completed | Met primary |
| — | NCT01388036 | Jul 2011 → May 2015 | — | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT02794025 | Jan 2010 → Jan 2013 | infectious disease with sepsis | Fujian Provincial Hospital | Completed | No outcome recorded |
| — | NCT01544959 | Jan 2010 → Jan 2013 | breast cancer | University of Sherbrooke | Completed | No outcome recorded |
| — | NCT01275911 | Jan 2009 → Jul 2010 | pain agnosia | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| — | NCT00756236 | Oct 2008 → Sep 2015 | myocardial ischemia | University of Oklahoma | Completed | No outcome recorded |
| Comparator or background therapy36 trials | ||||||
| Phase 0 | NCT04181606 Comparator | Feb 2022 → Apr 2023 | — | David N. Proctor, PhD | Completed | No outcome recorded |
| Phase 1 | NCT03347968 Comparator | Nov 2017 → Apr 2018 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT01951950 Comparator | Sep 2013 → May 2014 | brain neoplasm | Northwestern University | Completed | No outcome recorded |
| Phase 1 | NCT01741519 Comparator | Dec 2012 → Jan 2013 | — | AOP Orphan Pharmaceuticals AG | Completed | No outcome recorded |
| Phase 1 | NCT01652898 Comparator | Jul 2012 | — | AOP Orphan Pharmaceuticals AG | Completed | No outcome recorded |
| Phase 1/2 | NCT03892512 Comparator | Apr → Dec 2019 | cognitive disorder | Beni-Suef University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01431612 Comparator | Nov 2008 → Oct 2010 | ovarian cyst | Sodertalje Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04260685 Comparator | Feb → Jun 2020 | lumbar disk disease | Zagazig University | Completed | No outcome recorded |
| Phase 2 | NCT02098629 Comparator | May 2015 → Mar 2023 | myocardial infarction | Shantou University Medical College | Completed | No outcome recorded |
| Phase 2 | NCT02369900 Comparator | Mar 2015 → Dec 2019 | cardiac rhythm disease, hypotensive disorder, infectious disease with sepsis | Beth Israel Deaconess Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01313143 Comparator | Mar → May 2011 | — | AOP Orphan Pharmaceuticals AG | Completed | No outcome recorded |
| Phase 2/3 | NCT05850832 Comparator | Oct 2022 → Jan 2023 | — | Alexandria University | Completed | No outcome recorded |
| Phase 2/3 | NCT04356352 Comparator | Sep 2020 → Aug 2023 | — | Wake Forest University Health Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04081545 Background | Dec 2019 → Mar 2023 | substance-related disorder | Christine Oryhan | Completed | No outcome recorded |
| Phase 3 | NCT03998436 Comparator | Dec 2018 → Aug 2021 | ulcer of lower limbs | Novalead Pharma Private Limited | Completed | No outcome recorded |
| Phase 3 | NCT02563288 Comparator | Aug 2016 → Aug 2017 | brain aneurysm, brain neoplasm | George Papanicolaou Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02455440 Comparator | Mar 2014 → Jul 2015 | brain aneurysm | George Papanicolaou Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04086940 Comparator | Nov 2019 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT04264286 Comparator | Jul 2019 → Jul 2020 | — | Hospital de Base | Unknown | No outcome recorded |
| Phase 4 | NCT03612492 Comparator | Jul 2018 → Jul 2019 | — | Hospital de Base | Unknown | No outcome recorded |
| Phase 4 | NCT02967029 Comparator | Nov 2016 → Jul 2017 | hypotensive disorder | Istanbul University | Completed | No outcome recorded |
| Phase 4 | NCT02466542 Comparator | Jun 2015 → Feb 2017 | — | Hospital de Base | Completed | No outcome recorded |
| Phase 4 | NCT02327923 Comparator | Jan 2015 → Feb 2016 | gallstones | B.P. Koirala Institute of Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02062333 Comparator | Jan → Nov 2014 | tinnitus | TC Erciyes University | Completed | No outcome recorded |
| Phase 4 | NCT01628562 Comparator | Jun 2012 → Sep 2014 | cardiac rhythm disease, hypertensive disorder, myocardial ischemia | Diskapi Teaching and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01179113 Comparator | Jun 2011 → May 2015 | — | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
| — | NCT07846722 Comparator | Jul → Dec 2026 expected | — | Vasiliki Samartzi | Recruiting | No outcome recorded |
| — | NCT07660861 Comparator | Jun 2026 → Jun 2027 expected | intracranial berry aneurysm, intracranial hypertension | Fatih Sultan Mehmet Training and Research Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06376630 Comparator | Jan 2024 → Jan 2029 expected | coronary microvascular disorder, coronary stenosis, myocardial infarction | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Recruiting | No outcome recorded |
| — | NCT05567822 Comparator | Oct 2022 → Oct 2024 | chronic pain syndrome | Aretaieion University Hospital | Unknown | No outcome recorded |
| — | NCT06268275 Comparator | Sep 2022 → Feb 2024 | — | Khon Kaen University | Completed | No outcome recorded |
| — | NCT04507165 Comparator | Aug 2020 → Jul 2021 | — | Peking University People's Hospital | Unknown | Met primary |
| — | NCT01782898 Comparator | Jan 2013 → Dec 2014 | — | Northwestern University | Completed | No outcome recorded |
| — | NCT01212874 Comparator | Dec 2010 → Jun 2014 | hypertensive disorder | Loma Linda University | Completed | No outcome recorded |
| — | NCT00848770 Comparator | Jan 2008 → Dec 2010 | ischemic stroke | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| — | NCT00226096 Background | Nov 2005 → Sep 2007 | intracerebral hemorrhage | The George Institute | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 99 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Esmolol | “Propranolol (10 mg orally or via nasogastric tube, three times daily) or Esmolol (1 g in 40 mL saline, IV infusion at no less than 2 mL/h; use for no more than 48 hours. Beyond...” NCT06863558 ↗92“IV beta-blockers available through the inpatient pharmacy include metoprolol or esmolol, and IV calcium channel blockers include diltiazem and verapamil.” NCT04234477 ↗ “participants were given intravenous esmolol(cardioselective beta blocker) during induction of General Anesthesia before laryngoscopy and intubation.” NCT06065956 ↗ “Esmolol (1 g in 40 mL saline, IV infusion at no less than 2 mL/h; use for no more than 48 hours. Beyond 48 hours, switch to Propranolol)” NCT06863571 ↗ “May use esmolol as needed to treat SBP or HR” NCT04081545 ↗ “esmolol 1mg/kg (intravenous bolus)” NCT04507165 ↗ “20-100 μg/kg/min esmolol” NCT07603596 ↗ “Esmolol” NCT01782898 ↗ “Esmolol” NCT02116868 ↗ |
| Known as | ASL-8052 | ChEMBL registry synonym — accepted as the source's own label CHEMBL768 ↗ |
| Known as | ASL-8052-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL768 ↗ |
| Known as | Brevibloc | “three doses of esmolol (0.5, 1, and 1.5 mg/kg BW) in an i.v. formulation (Brevibloc® 100 mg/10 mL). PK and PD parameters, safety, and tolerability were assessed.” PMID 28091703 ↗ Jan 2017 |
| Known as | breviblock | “loading dose of esmolol(breviblock) 1 mg/kg in 50 ml isotonic saline” NCT04086940 ↗ |
| Known as | Clol | ChEMBL registry synonym — accepted as the source's own label CHEMBL768 ↗ |
| Known as | Esmolol Hcl | “Esmolol Hcl 10Mg/Ml Inj” NCT07019818 ↗ |
| Known as | Esmolol Hydrochloride | “A Prospective, Multicenter, Randomized, Double-Blind, Phase 3 Study to Evaluate the Safety and Efficacy of a Gel Formulation of Esmolol Hydrochloride (Galnobax®) in Treating...” NCT03998436 ↗8“Esmolol hydrochloride administered as intravenous bolus injection at low (0,5mg/kg), medium (1mg/kg) and high dose (1,5mg/kg) in 15/30/45 seconds once per subject” NCT01652898 ↗ “containing either Esmolol (Esmolol hydrochloride; Baxter Healthcare Corp., Deerfield, USA) or MgSo4 ( Egyptian international pharmaceutical indust., EYGPT)” NCT05850832 ↗ “Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride )” NCT03892512 ↗ “esmolol hydrochloride is a beta blocker suitable for venous use in the form of continuous infusion.” NCT03743103 ↗ “initially by titration of intravenous esmolol hydrochloride” NCT00302692 ↗ “Drug: Esmolol Hydrochloride” NCT02967029 ↗ |
| Action | Inhibit | “continuous perioperative beta-adrenergic blockade” PMID 19336536 ↗ Mar 20092“Beta-1 adrenergic receptor antagonist” CHEMBL768 ↗ “Beta-2 adrenergic receptor antagonist” CHEMBL768 ↗ |
| Modality | Other / unclassified | “The β-blocking drugs, esmolol and labetalol have been used as an alternative to short-acting opioid analgesics for controlling the transient, acute autonomic responses during surgery” NCT01114997 ↗ |
| Route | Intravenous | “titration of intravenous esmolol hydrochloride” NCT00302692 ↗ |
| Target | ADRB1 | “Beta-1 adrenergic receptor antagonist” CHEMBL768 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor antagonist” CHEMBL768 ↗ |